Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 8/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247915 | 1.00 | SLC9A1 (0.48) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL7655989 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL248385 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL18272394 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL248384 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL18272446 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL15196464 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL12915852 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL29488083 | 0.86 | FFAR1 (0.50) | SLC9A1HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL22654465 | 0.85 | KDM1A (0.58) | SLC9A1KDM1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183412-B2 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | claimed |
| US-20110190520-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2011-08-04 | — | — | US | claimed |
| US-20060258879-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | US | claimed |
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20100004444-A1 | Novel Triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20080234481-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-7381828-B2 | Triazolo pyrimidine compounds | AstraZēneca AB (SE) | 2008-06-03 | — | — | US | disclosed |
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | disclosed |
| EP-1299390-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE IN THE PREPARATION OF A TRIAZOLO -PYRIMIDINE CARBA NUCLEOSIDE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20060258879-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | US | disclosed |
| US-7122695-B2 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20060041132-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | SLC9A1 226/4885HTR2A 1881/4885HTR2C 2143/4885 |
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | SLC9A1 4551/4885HTR2A 302/4885HTR2C 118/4885 |
| US-20060258879-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | MCCC2, DHPS, CYP3A4 | SLC9A1 4322/4885HTR2A 3833/4885HTR2C 4039/4885 |
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | SLC9A1 4604/4885HTR2A 2776/4885HTR2C 2090/4885 |
| US-20080234481-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | SLC9A1 4604/4885HTR2A 2776/4885HTR2C 2090/4885 |
| US-20060041132-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | SLC9A1 4604/4885HTR2A 2776/4885HTR2C 2090/4885 |
| US-20110190520-A1 | Process for the preparation of cyclopropyl carboxylic acid esters and derivatives | MCCC2, DHPS, CYP3A4 | SLC9A1 4322/4885HTR2A 3833/4885HTR2C 4039/4885 |
| US-20100004444-A1 | Novel Triazolo pyrimidine compounds | TYMS, TYMP, DPYD | SLC9A1 4604/4885HTR2A 2776/4885HTR2C 2090/4885 |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | SLC9A1 226/4885HTR2A 1881/4885HTR2C 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.